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INTERAKSI ANTARA SISTEM RENIN ANGIOTENSIN DAN RESEPTOR 
ADRENERGIK-α1 PADA SALURAN DARAH BERINTANGAN GINJAL DALAM 
DIABETIS MELITUS DAN HIPERTENSI 
 
ABSTRAK 
 
α1-adrenoseptor dan reseptor subjenis angiotensin jenis 1 (AT1) memainkan peranan 
penting dalam pengawalaturan hemodinamik ginjal pada peringkat vaskulatur 
rintangan ginjal. Ianya memang diketahui yang diabetis melitus mampu merosakkan 
salur darah dan saraf periferi, dan ini diburukkan lagi oleh keadaan darah tinggi. Kajian 
ini dilakukan bagi mengkaji peranan fungsi subjenis α1-adrenoseptor dan reseptor AT1 
pada peringkat vaskulatur rintangan ginjal dalam diabetis melitus, darah tinggi, dan 
gabungan kedua-dua keadaan patologikal, dan sebarang kemungkinan interaksi fungsi 
intrarenal antara α1-adrenoceptors dan renin angiotensin setempat. Tikus normotensif 
WKY dan SHR telah digunakan. Diabetis mellitus diaruh dengan satu dos tunggal 
streptozotosin pada 55 mg.kg-1 secara intraperitoneal. Berat badan, jumlah air 
diminum, jumlah air kencing, paras glukosa dan natrium darah, dan tahap penyingkiran 
natrium melalui air kencing dimantau. Semasa kajian akut, tikus-tikus ini dibius dengan 
natrium pentobarbiton pada 60 mg.kg-1 secara intraperitoneal. Lanjutan trakeostomi 
untuk membolehkan pernafasan berbantu, vena jugular kiri dan arteri karotid kanan 
dimasuk tiub bagi tujuan pemberian berterusan air salin dan pengukuran tekanan 
darah arteri purata. Selesai melakukan pembelahan abdomen garis tengah, organ 
dalaman abdomen dialihkan secara berhati-hati ke sebelah kanan bagi mendedahkan 
ginjal kiri. Satu prob pengaliran elektromagnetik dipasang pada arteri renal untuk 
pengukuran pengaliran darah ginjal. Elektrod dwipolar digunakan untuk merangsang 
saraf renal. Sebaik sahaja pembedahan selesai, 2 ml salin diberi secara intravena 
sebagai primer, dan tikus distabilkan untuk tempoh satu jam. Pengurangan pengaliran 
darah ginjal terhadap rangsangan saraf elektrikal (1, 2, 4, 6, 8 dan 10 Hz pada 15V, 2 
ms), dos bolus fenilefrin (0.25, 0.50, 1.00 dan 2.00 μg), metoksamin (0.50, 1.00, 2.00 
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dan 4.00 μg) dan angiotensin II (2.50, 5.00, 10.00 dan 20.00 ng) ditentukan dalam 
kehadiran 5-metilurapidil (5.00 dan 10.00 μg.kg-1 termasuk 1.25 dan 2.50 μg.kg-1.hr-1), 
kloroetilklonidin (5.00 dan 10.00 μg.kg-1 termasuk 1.25 dan 2.50 μg.kg-1.hr-1), BMY7378 
(100.00 dan 200.00 μg.kg-1 termasuk 25.00 dan 50.00 μg.kg-1.hr-1), amlodipin (200.00 
dan 400.00 μg.kg-1 termasuk 50.00 dan 100.00 μg.kg-1.hr-1), perindopril (0.20 mg.kg-1) 
dan losartan (10.00 mg.kg-1), dan tekanan darah arteri purata dimantau. Data, purata + 
s.e.m., dianalisis dengan ANOVA-satu hala atau -dua hala diikuti dengan post-hoc 
Bonferroni pada tahap signifikan 5%. Pengurangan secara signifikan dalam berat 
badan, peningkatan ketara air diminum dan penghasilan air kencing diperhatikan di 
dalam haiwan diabetik berbanding dengan haiwan tidak diabetik. Nilai asas tekanan 
darah arteri purata kekal konsisten sepanjang kajian kecuali di dalam beberapa 
kumpulan, manakala nilai asas pengaliran darah renal kekal tidak berubah di dalam 
kesemua kumpulan ujikaji. Dari respon vasokonstriktor renal, subjenis α1A-
adrenoseptor dan reseptor pos-sinaptik AT1 memainkan peranan penting dalam 
mengawalatur vasokonstriksi salur darah rintangan dalam tikus WKY dan SHR bukan 
diabetik dan diabetik. Fungsi adrenoseptor subjenis α1B and α1D, dan Ang II beraliran 
amat dipengaruhi oleh keadaan penyakit diabetis melitus dan tekanan darah tinggi. 
Dalam tikus nondiabetik WKY, interaksi di antara sistem renin angiotensin dan 
adrenoseptor subjenis α1 berlaku secara utama melalui adrenoseptor subjenis α1B dan 
reseptor AT1, dan di bawah pengaruh diabetis melitus dan tekanan darah tinggi 
adrenoseptor subjenis α1A dan α1D menjadi lebih terlibat di dalam interaksi ini. Ang II 
beraliran mempunyai kesan lebih ketara ke atas respon dimediasi oleh adrenoseptor 
α1 berbanding oleh reseptor AT1. Kesimpulannya, interaksi dalam ginjal di antara 
reseptor adrenergik α1 dan reseptor AT1 wujud pada peringkat salur darah rintangan 
ginjal, dan ini dipengaruhi secara ketara oleh keadaan penyakit diabetis melitus dan 
tekanan darah tinggi. 
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INTERACTION BETWEEN THE RENIN ANGIOTENSIN SYSTEM AND 
α1-ADRENERGIC RECEPTORS AT THE RENAL RESISTANCE VESSELS 
IN DIABETES MELLITUS AND HYPERTENSION 
 
ABSTRACT 
 
α1-adrenoceptors and angiotensin type 1 (AT1) receptor subtype play important roles in 
the regulation of renal haemodynamic at the level of renal resistance vasculature. It is 
known that diabetes mellitus could damage the peripheral blood vessels and nerves, 
and is worsen by hypertensive state. This study was designed to examine the 
functional role of α1-adrenoceptor subtypes and AT1-receptor at the renal vasculature 
resistance in diabetes mellitus, hypertension and combination of both pathological 
states, and any possible intrarenal functional interaction between the α1-adrenoceptors 
and local renin-angiotensin systems. Normotensive WKY and SHR rats were utilized. 
Diabetes mellitus was induced by a single dose of streptozotocin at 55 mg.kg-1 
intraperitoneally. Body weight, water intake, urine output, plasma glucose and sodium 
levels, and urinary sodium excretion were monitored. During the acute study, the rats 
were anaesthetized with pentobarbitone sodium at 60 mg.kg-1 intraperitoneally. 
Following tracheostomy to allow facilitated breathing, the left jugular vein and the right 
carotid artery were cannulated for continuous infusion of saline and measurement of 
the mean arterial blood pressure, respectively. Having performed a midline abdominal 
incision, the internal abdominal organs were carefully displaced to the right side to 
expose the left kidney. An electromagnetic flow probe was placed on the renal artery 
for renal blood flow (RBF) measurement. Bipolar electrodes were used to stimulate 
renal nerve. Upon completion of surgery, 2 ml of saline was given intravenously as a 
primer, and one hour period of stabilization was observed. Reductions in RBF to 
electrical stimulation (1, 2, 4, 6, 8, and 10 Hz at 15V, 2 ms), bolus doses of 
phenylephrine (0.25, 0.50, 1.00 and 2.00 μg), methoxamine (0.50, 1.00, 2.00 and 4.00 
μg) and angiotensin II (2.50, 5.00, 10.00 and 20.00 ng) were determined in the 
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presence of 5-methylurapidil (5.00 and 10.00 μg.kg-1 plus 1.25 and 2.50 μg.kg-1.hr-1), 
chloroethylclonidine (5.00 and 10.00 μg.kg-1 plus 1.25 and 2.50 μg.kg-1.hr-1), BMY7378 
(100.00 and 200.00 μg.kg-1 plus 25.00 and 50.00 μg.kg-1.hr-1), amlodipine (200.00 and 
400.00 μg.kg-1 plus 50.00 and 100.00 μg.kg-1.hr-1), perindopril (0.20 mg.kg-1) and 
losartan (10.00 mg.kg-1), and mean arterial pressure (MAP) were monitored. Data, 
means + s.e.m., were analyzed with one- and two-ways analysis of variance followed 
by Bonferroni post hoc with the significance level of 5%. Significant reductions in body 
weight, higher water intake and urine output were observed in diabetic as compared to 
nondiabetic animals. Baseline values of MAP remained consistent throughout study 
except in few groups, whereas the RBF values remained unaltered in all experimental 
groups. From the renal vasoconstrictor responses, the α1A-adrenoceptor subtype and 
postsynaptic AT1-receptors are functionally important in mediating the vasoconstriction 
of the resistance vessels in nondiabetic and diabetic WKY and SHR rats. Functionality 
of α1B- and α1D-adrenoceptor subtypes and circulating Ang II were greatly influenced by 
the pathological states of diabetes mellitus and hypertension. In nondiabetic WKY, the 
interaction between the renin angiotensin system and α1-adrenoceptor subtypes 
occurred mainly through α1B-adrenoceptor subtype and AT1-receptor, and under the 
influence of diabetic and hypertensive conditions, the α1A- and α1D-adrenoceptor 
subtypes became increasingly involved in the interaction. Circulating Ang II exerted 
greater effects on the responses mediated by α1-adrenergic receptors than by AT1-
receptors. In conclusion, intrarenal interaction between the α1-adrenergic receptors and 
AT1-receptor exists at the level of renal resistance vessels, and this is greatly 
influenced by the pathological conditions of diabetes mellitus and hypertension. 
 
 
 
 1
CHAPTER 1 
 
INTRODUCTION 
 
The maintenance of cardiovascular homeostasis represents a balance between 
the volume of blood in the vascular system, the pumping effectiveness of the heart, the 
regulation of arterial vascular resistance and the function of the kidney to ensure 
appropriate level of fluid reabsorption and excretion. Dysfunction of any one element of 
this cardiovascular-renal control interaction can be responsible for the development of 
a chronically elevated blood pressure (BP), or hypertension which exists in up to 20% 
of the adult population of most developed nations (Genest, 1994). The sustained 
elevated BPs impose a burden on the cardiovascular system, in particular on arteries, 
arterial resistance vessels, the cerebrovascular circulation, the heart and the kidneys, 
and places these individuals at increased risk of target-organ damages, such as stroke, 
myocardial infarction, left ventricular hypertrophy, heart failure and end-stage renal 
failure (ESRF) (Chobanian et al., 2003). 
A dramatic increase in patients with ESRF has been observed. In 1991, about 
190,000 persons in the United States either underwent dialysis or received a renal 
transplant for ESRF (Klag et al., 1996), and the major underlying causes were diabetic 
nephropathy and high BP. High BP is a strong independent risk factor for ESRF. The 
increase in risk associated with higher BP is graded and continuous throughout the 
distribution of blood pressure readings above the optimal level. The risk of ESRF in 
men with hypertension, as compared with men with optimal levels of BP, increases 
with each of the four successively more severe stages of hypertension. Systolic BP 
before treatment is a stronger predictor of end-stage renal disease than is diastolic 
pressure. Overall, the rates of ESRF are markedly higher for men with hypertensive 
levels of both systolic and diastolic BP (Klag et al., 1996). Observational and clinical 
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trials involving patients with renal insufficiency have also demonstrated that lowering 
BP preserves renal function. 
The central role of the kidney in the regulation of BP in many pathophysiological 
conditions has been supported by the experimental work of Guyton (1989) and the 
clinical evidence of Hollenberg (1980) who reported that in young essential 
hypertensive patients, up to two thirds could be shown to have either, or both, a slight 
reduction in renal blood flow or defective ability to excrete a saline volume load. Among 
the contributable factors are increased activity of the renin-angiotensin system and the 
renal sympathetic nervous system. Over-activation of these systems leads to retention 
of sodium and water, and increased vasoconstriction of peripheral resistance vessels 
that increases the vascular resistance against the blood flow, and thus the BP. 
 
1.1 The kidney 
 
The kidney is one of the vital organs of the body, and plays important roles in 
maintaining the internal environment of the body within its optimal condition. The 
kidney performs a variety of functions as below: 
1.  Regulation of water, inorganic ion balance and internal environment, 
2.  Removal of metabolic waste products, such as urea, uric acid and 
creatinine, from the blood and their excretion in the urine, 
3.  Removal of foreign chemicals, such as drugs, pesticides, food additives, 
from the blood and their excretion in the urine, 
4.  Synthesizing glucose from amino acids and other precursors to be 
released into the blood during prolonged fasting (gluconeogenesis), 
5.  Production of hormones/enzymes: 
• Erythropoietin, which controls erythrocyte production (erythropoiesis), 
• Renin, an enzyme that controls the formation of angiotensin and 
involves in the regulation of blood pressure and sodium balance, 
• 1,25-dihydroxyvitamin D, which influences calcium balance. 
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1.1.1 The nephron 
The single functional unit of the kidney is nephron, and there are approximately 
1 million nephrons in each kidney. Each nephron is made of a renal corpuscle and a 
tubule that extends from the renal corpuscle. The renal corpuscle is the initial filtering 
component of the kidney, forming filtrate from blood that is free from cells and protein. 
The filtrate enters the tubule through which substances are added to or removed from 
it. The remaining fluid at the end of each nephron drains into the collecting ducts and 
exits the kidney as urine. 
 
 
 
 
 
 
 
 
 
 
 
 
1.1.1.a  Renal Corpuscle 
Each renal corpuscle is constituted by glomerulus (also called glomerular 
capillaries) and Bowman’s capsule (Figure 1.2). The glomerulus is a compact tuft of 
interconnected capillary loops with a diameter of approximately 200μm, and the 
Bowman’s capsule is a fluid-filled capsule into which the glomerulus protrudes into. 
The part of Bowman’s capsule in contact with the glomerulus becomes pushed inwards 
without touching the opposite side of the capsule, forming a fluid-filled space, known as 
Bowman’s space, within the capsule. As blood flows through the glomerulus from the  
Figure 1.1: Gross anatomy of the kidney 
[Adapted from Widmaier et al., 2006] 
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Figure 1.2: Renal corpuscle and the ultrafiltration process 
[Adapted from Widmaier et al., 2006] 
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afferent arteriole, about 20 percent of the protein-free plasma filters into Bowman’s 
space while the remaining blood leaves the glomerulus via the efferent arteriole. 
A filtration barrier separates the blood in the glomerulus from the glomerular 
filtrate in Bowman’s space. This physical barrier is made up of three layers, namely the 
single-celled capillary endothelium, basal lamina (a noncellular proteinaceous layer of 
basement membrane, and podocytes (a single-celled epithelial lining of Bowman’s 
capsule). The podocytes are specialised cells that have an octopus-like structure with a 
large number of foot processes. The fluid is filtered through the endothelial cells, the 
basal lamina, and finally between the foot processes of the podocytes (Widmaier et al., 
2006). 
 
1.1.1.b  The tubules 
The tubule is continuous with a Bowman’s capsule. It is hollow and cylindrical in 
shape with a single layer of epithelial cells. As illustrated in Figure 1.3, the tubule is 
divided into few segments, namely the proximal tubule, the loop of Henle, and the 
distal convoluted tubule. Fluid course from the distal convoluted tubule into the 
collecting duct system that is made up by the cortical collecting duct and medullary 
collecting duct. Finally, the urine drains into the kidney’s central cavity, the renal pelvis, 
which is continuous with the ureter (Widmaier et al., 2006). 
The proximal tubule comprises of a convoluted portion and a straight portion. 
The luminal surface of the epithelial cells of the proximal tubule is lined by microvilli to 
enhance reabsorption processes. The loop of Henle is a sharp, hairpin-like loop 
comprising a descending limb and an ascending limb (Widmaier et al., 2006). In the 
collecting ducts, principal cells (P cells) and intercalated cells (I cells) are part of the 
epithelial cells with the P cells predominating. The P cells involve in the Na+ ion and 
vasopressin-stimulated water reabsorption, whereas the I cells are responsible for H+ 
secretion and HCO3- ion transport (Ganong, 1999). 
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Figure 1.3: Nephron 
[Adapted from Widmaier et al., 2006] 
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  There are two important regions in the kidney. The outer region is called the 
renal cortex, and the inner region is the renal medulla that is further divided into three 
zones, namely the outer stripe of the outer medulla, the inner stripe of the outer 
medulla, and the inner medulla. All the renal corpuscles are located within the cortex 
whereas the loops of Henle extend at varying lengths from the cortex down into the 
medulla giving rise to two different types of nephrons, the cortical and juxtamedullary 
nephrons. Cortical nephrons are the majority type with 85% share. Their renal 
corpuscle are located in the outer cortex, and their loops of Henle are short and do not 
penetrate deep into the medullary region. On the other hand, the renal corpuscles of 
the juxtamedullary nephrons are found closest to the cortical-medullary junction, and 
their loops extend deep into the medulla. These long extending loops produce an 
osmotic gradient by generating a hypertonic medullary interstitium for the reabsorption 
of water (Widmaier et al., 2006). 
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1.1.2  Renal circulation 
The kidney is a highly vascularised organ, and it receives approximately a 
quarter of the cardiac output, which is about 1200 – 1300 ml.min-1 of blood. All the four 
different regions of the kidney are perfused not equally; average total tissue blood flow 
in the renal cortex is 700 ml.min-1.100 g-1, near the junction of the cortex and the outer 
medulla is 300 ml.min-1.100 g-1, in the inner stripe of the outer medulla is 200 ml.min-
1.100 g-1, and in the inner medulla is between 50 to 100 ml.min-1.100 g-1 (Aukland, 
1980; Knox et al., 1984; Cupples, 1986). The blood enters the kidney through the renal 
artery that arises from the abdominal aorta and leaves the kidney by the renal vein, 
both at the hilum, respectively. The renal artery branches out into the smaller interlobar 
artery, the arcuate artery, the interlobular artery, the afferent arteriole, the glomerulus, 
the efferent arteriole, and peritubular capillary. From here onwards, the blood vessels 
merge to form bigger vessels, the interlobular veins and eventually the renal vein 
(Widmaier et al., 2006).  
 The renal circulation is unique in such a way that it includes two sets of 
arterioles (afferent and efferent arterioles) and two sets of capillaries (glomerulus and 
peritubular capillaries). The afferent arterioles (preglomerular arterioles) are short 
branches of interlobular arteries and they divide into capillary vessels to form the 
glomerulus. The capillaries coalesce to form the efferent arterioles (postglomerular 
arterioles), which in turn break up into either the peritubular capillaries that surround 
the tubules in the cortical nephron or form long hairpin loops of capillaries, known as 
vasa rectae, that loop deeply into the medulla along side the loops of Henle of the inner 
cortical and juxtamedullary nephron (Ganong, 1999; Widmaier et al., 2006). As 
illustrated in Figure 1.4, the efferent arterioles of the juxtamedullary nephrons enter the 
outer stripe of the outer medulla and divide into vasa rectae that descend into the inner 
stripe of the outer medulla and form vascular bundles. The descending vasa rectae 
(DVR) in the centre of the bundles continue into the inner medulla whereas the DVR on 
the outer margins of the bundles give rise to a capillary plexus between the vascular 
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bundles in the outer medulla. The DVR found in either the outer or inner medulla divide 
and eventually coalesce into ascending vasa recta that carry reabsorbed solutes and 
water from the medulla back into the venous circulation (Kriz, 1981). Approximately 
90% of the renal blood flow remains in the renal cortex and perfuses the peritubular 
capillary bed. The remaining 10% of the blood flow perfuses the renal medulla through 
the vasa rectae (Kriz, 1981; Zimmerhackl et al., 1987; Cupples et al., 1988). 
 
 
 
Figure 1.4: Renal microcirculation into the regions of renal cortex (C), the outer stripe
of the outer medulla (OS), the inner stripe of the outer medulla, and the inner medulla
(IM). Arterial vessels, descending vasa recta (DVR), and capillaries are depicted on
the left; the ascending vasa recta and venous circulation are in the middle; and the
renal tubular system on the right. 
[adapted from Mattson, 2003] 
C 
OS
IS
IM
 10
 
1.1.2.a  Renal regional circulation 
 Several functional studies have demonstrated that the blood flow in the renal 
medullary circulation can indeed be regulated independently of renal cortical blood 
flow. Such studies have shown that renal medullary blood flow increases after an 
elevation in renal perfusion pressure despite efficient autoregulation of renal blood 
flow, renal cortical blood flow, and glomerular filtration rate (Mattson et al., 1993; 
Cowley, 1997; Evans et al., 2000). The mechanisms that allow modulation of renal 
medullary blood flow in the absence of changes in renal cortical perfusion are not clear, 
but evidence obtained from both morphological and physiological studies indicates that 
the appropriate regulatory components exist in the medullary circulation that makes it 
possible for the blood flow in this part of the kidney to be selectively regulated.  
The afferent and efferent arterioles are small resistance vessels that regulate 
renal microcirculation and glomerular filtration. Helou and Marchetti (1997) have 
described two subpopulations of efferent arterioles that display morphological, 
topological, and functional differences. Morphologically, muscular efferent arterioles 
(mEA) have a thick, regular, and muscular wall, and terminate as vasa rectae. The 
mEA of the juxtamedullary nephrons descend into the outer medulla and branch into 
the vasa rectae in the outer stripe of the outer medulla. These efferent arterioles 
contain up to four layers of smooth muscle and a layer of endothelial cells. The 
endothelial cell layer is continuous from the efferent arterioles to the vasa rectae, but 
the smooth muscle of the efferent arterioles is gradually replaced by pericytes as the 
vasa rectae divide and branch in the medulla (Kriz, 1981). Pericytes are cells with a 
phenotype similar to that observed in vascular smooth muscle (Herman and D’Amore, 
1985; Nehls and Drenckhahn, 1991; Park et al., 1997), and are found in both the outer 
and inner medulla (Park et al., 1997). Cultured pericytes have been shown capable of 
contracting both tangentially and circumferentially (Murphy and Wagner, 1994), and 
this makes the pericytes ideally suited to modulate blood flow in the vasa rectae by 
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altering vessel diameter, and provides a mechanism by which medullary blood flow can 
be regulated in response to circulating hormones or locally released paracrine and 
autocrine factors (Mattson, 2003). On the other hand, thin efferent arterioles (tEA) have 
a thinner, irregular and less muscular wall, and terminate as peritubular capillaries. 
Based on functional aspect, in response to angiotensin II (Ang II), mEA display higher 
increases in intracellular Ca2+ concentration than tEA, but mEA are slightly less 
sensitive to Ang II than are tEA (Helou and Marchetti, 1997; Helou et al., 2003). 
However, mEA from juxtamedullary nephrons in AT1A receptor-null mice do not exhibit 
a contractile response under Ang II stimulation suggesting that mouse mEA are devoid 
of AT1B receptors (Harrison-Bernard et al., 2003). 
Studies using isolated and cannulated DVR on vascular constrictor and dilator 
responses have demonstrated that the vascular diameter of the DVR can be 
independently altered by various vasoactive agents involving among others, changes 
in intracellular calcium and nitric oxide, and cell signalling pathways (Pallone, 1994; 
Silldorff et al., 1996; Pallone et al., 2000; Rhinehart and Pallone, 2001; Zhang et al., 
2002). These studies further establish that the regulation of blood flow within the renal 
medulla is independent of changes in renal cortical vascular resistance. 
 
1.1.2.b  Autoregulation of renal circulation 
Renal blood flow can be altered by many conditions, among others are normal 
physiological changes such as exercise, pain, heat and posture, and diseases that 
results in decreased or loss of renal tissues, or changes in the arterioles and 
glomerular capillaries such as hypertension and diabetes mellitus (De Wardener, 
1969). The renal microvessels have the ability to autoregulate the total and regional 
renal blood flow (RBF) to maintain the optimum perfusion pressure by contracting upon 
pressure rise and dilating upon pressure drop (Johnson and Intaglietta, 1976). This is 
because the intrarenal blood flow is very important for normal renal functions and any 
alteration to blood flow will in turn affect the renal function (Regan et al., 1995). 
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 Renal autoregulation can be defined as the kidney’s ability to alter its own 
vascular resistance in response to changes in arterial pressure to maintain essentially 
constant RBF and glomerular filtration rate (GFR) over a range of arterial pressure 
from 90 to 180 mmHg (Cupples, 1993). Glomerular capillary pressure (Pgc) is a function 
of the balance between afferent and efferent vascular resistances, as well as the level 
of systemic blood pressure.  Increased Pgc has been suggested to be a major 
pathogenetic factor in the development of glomerular sclerosis in hypertensive renal 
disease in rats (Ofstad et al., 1992). Lowering of the increased Pgc has been shown to 
attenuate glomerular degeneration and preserve renal function (Anderson et al., 1986; 
Jackson and Johnston, 1988; Brunner et al., 1989; Tolins and Raij, 1990; Wenzel et 
al., 1992; Dworkin et al., 1993; Griffin et al., 1994, 1995). Adjusting the renal vascular 
resistance, mainly involving the afferent vessels, may prevent variations in Pgc during 
everyday transitory fluctuations of the systemic blood pressure (Navar, 1978). In 
experimental conditions, autoregulation keeps both RBF and Pgc constant within a wide 
range of acute pressure variations. When hypertension becomes chronic, the 
autoregulation is reversibly reset toward higher blood pressures, whereas the capacity 
of autoregulation seems to be maintained (Iversen et al., 1987). However, an increase 
in Pgc seems to follow long-standing hypertension (Iversen et al., 1998). Among the 
many controllers of volume and sodium excretion (Dietz et al., 2001; Gabrielsen et al., 
2001; Lohmeier et al., 2001; Peterson et al., 2001; Andersen et al., 2002; Schou et al., 
2002), blood pressure appears to be among the most potent (Mattson, 2003). When in 
the well-hydrated state, the renal medullary circulation loses its capacity to 
autoregulate (Mattson, 2003). Accordingly, hypertension will wash out the osmotic 
gradient, thereby limiting the amount of fluid excreted. 
Autoregulation of RBF is mediated by a rapid myogenic response and a slower 
tubuloglomerular feedback mechanism (TGF). The myogenic response is, to some 
degree, an opened-loop mechanism meaning that the local vasoaction will not directly 
feedback onto the input signal. Conversely, TGF operates in a closed-loop mode. The 
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TGF responds with a frequency of 0.02 to 0.06 Hz, and has a half-life of roughly 10 to 
30 s, whereas the myogenic response is quicker, acting in a range between 0.1 and 
0.3 Hz with a half-life of 1 to 4 s (Moore, 1984; Schnermann and Briggs, 1989; Holm et 
al., 1990; Moore and Casellas, 1990; Holstein-Rathlou et al., 1991; Holstein-Rathlou, 
1993; Janssen et al., 1995; Cupples and Loutzenhiser, 1998; Just et al., 1998;  Walker 
et al., 2000; Wang et al., 2000). Both mechanisms due to their different frequency 
properties, contribute differently to the response to slow and rapid pressure ramps. 
Slow pressure changes may elicit a predominant TGF response, whereas rapid 
pressure changes also involve the myogenic response (Flemming et al., 2001). 
The key feature that incorporates the TGF simply relates the distal tubule inflow 
to the afferent arteriolar resistance, such that increases in distal tubular inflow result in 
vasoconstriction while decreases in flow lead to vasodilation. The distal tubular 
feedback mechanism mediates autoregulatory adjustments in renal vascular resistance 
(Navar, 1978). The TGF is known to reset during sustained alterations of arterial 
pressure (Selen and Persson, 1983), and it has been demonstrated that Ang II, at 
concentrations that do not alter renal resistance, increases the magnitude of TGF 
response (Ploth et al., 1979; Mitchell and Navar, 1988). Ang II blockade prevents 
resetting of autoregulation to operate at lower arterial pressure and RBF, and also 
impairs operation of the TGF (Cupples, 1993). This finding is compatible with an 
attenuation of TGF during ACE inhibition (Sorenson et al., 2000). It has been shown 
that TGF responses were also absent in ACE-deficient (Traynor et al., 1999) as well as 
in AT1A receptor-deficient (Schnermann et al., 1997) mice, and could be restored to 
near-normal levels with Ang II (Traynor et al., 1999). Feldberg et al. (1995), using 
simulation studies, concluded that the myogenic response is a prerequisite to obtaining 
any degree of autoregulation of RBF by the TGF mechanism. On the contrary, 
myogenic oscillations can be present when TGF is absent (Navar, 1998). 
Resetting of the RBF autoregulation serves to protect the glomerular capillaries 
from the variations of the systemic pressure. When arterial pressure is reduced 
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acutely, the magnitude of TGF response also decreases proportionally (Schnermann 
and Briggs, 1989) but recovers to control levels after 20 minutes despite continuing low 
pressure (Selen and Persson, 1983). Moreover, Holm et al., (1990) have shown that 
release of a suprarenal aortic clamp causes a short-lived hyperaemia followed by 
profound renal vasoconstriction that decays over 20 minutes. The vasoconstriction 
could be blocked by an angiotensin converting enzyme inhibitor, and they concluded 
that it reflected the operation of autoregulation since the vasoconstriction was pressure 
induced. It has been reported that the RBF autoregulation curve was reset toward 
higher pressure values during acute renal sympathetic nerve stimulation in dogs 
(Holdaas et al., 1981), hypertensive young SHR (Azar et al., 1979), and the non-
clipped kidney in two kidney-one clip (2K1C) hypertensive rats (Iversen et al., 1986). It 
is possible that resetting of blood flow autoregulation is a general mode of reaction 
when the perfusion pressure is increased, and it is expected to be a continuous 
process during the development of systemic hypertension. 
 Renal tissue damage does influence the resetting of the autoregulation. The 
resetting of RBF autoregulation seems to be perfect in hypertensive young 
spontaneously hypertensive rats (SHR) where the glomerular capillary pressure is kept 
normal (Azar et al., 1979, Iversen et al., 1987). However, in 36-week-old SHR, the 
glomerular capillary pressure is slightly increased when compared with age-matched 
WKY (Bank et al., 1983) indicating less perfect resetting of the autoregulation in SHR, 
possibly because of the greater tissue damage. Nephron loss increases the glomerular 
capillary pressure in the remnant nephrons (Azar et al., 1977). The glomerular capillary 
pressure has also been reported to be elevated in the non-clipped kidney in the 2K1C 
rat (Steiner et al., 1982), the DOCA-salt hypertensive rats (Dworkin et al., 1982), and in 
the Milano hypertensive rats (Baer and Bianchi, 1978). 
 Animal experiments have demonstrated significantly different effects of 
antihypertensive drugs on RBF autoregulation. Calcium channel blockers abolish RBF 
autoregulation (Navar et al., 1986) by eliminating the macula densa response (Mitchell 
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and Navar, 1990) whereas preserved autoregulation during resetting, caused by 
treatment with α1-adrenoceptor blocker and angiotensin converting enzyme inhibitor 
were observed (Navar et al., 1986; Iversen et al., 1987; Kvam et al., 1998). Hence, it is 
important that the preferable antihypertensive agents should not only reduce arterial 
blood pressure but also preserve RBF autoregulation and a normal Pgc. 
Antihypertensive drugs that abolish RBF autoregulation could be deleterious to the 
kidney if the systemic blood pressure is not reduced sufficiently.  
 
1.1.3 Role of the kidney in the long-term regulation of arterial pressure 
The theoretical importance of the kidney in the control of arterial pressure and 
the concept that alterations in renal function lead to adjustments in arterial blood 
pressure was first introduced by Guyton and colleagues (1974). Although arterial blood 
pressure is controlled by many regulatory systems, it is proposed that the kidney, 
through its ability to regulate extracellular fluid volume, is the dominant long-term 
controller of arterial pressure (Guyton et al., 1999). A key feature of this control system 
is pressure natriuresis, or the ability of the kidneys to respond to changes in arterial 
pressure by altering the renal excretion of salt and water (Reinhart et al., 1995; 
Lohmeier et al. 2000).  
The importance of the renal capacity to excrete sodium and water for the level 
of sustained arterial pressure of an organism has been revealed by system analyses of 
arterial pressure regulation (Guyton et al., 1999). Support for the important role of the 
kidney for long-term arterial pressure regulation, and for the development and 
maintenance of genetic forms of arterial hypertension comes from renal transplantation 
studies in patients and experimental animals (Rettig et al., 1993, 1996). Renal 
transplant studies performed between hypertensive and normotensive strains of rats 
have demonstrated that the long-term level of arterial pressure in the recipient is 
dependent on the genetic background of the donor kidney. Transplantation of the 
kidney from the SHR, the Dahl salt-sensitive rat, the Milan hypertensive rat, the stroke-
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prone SHR, and the Prague hypertensive rat into histocompatible normotensive 
recipients induces arterial hypertension in the recipient (Cowley, 1992; Rettig et al., 
1993; Mattson and Cowley, 1999). The opposite experiments have also been 
successfully performed where the kidney from normotensive donor rats transplanted 
into bilaterally nephrectomized SHR combined with immunosupression lowers arterial 
blood pressure in SHR (Patschan et al., 1997). 
Following transplantation of a kidney from young SHR donors into 
normotensive histocompatible recipients, hypertension develops within a few weeks 
and reaches a stable level within 6 – 8 weeks after renal transplantation (Rettig et al., 
1990). The development of renal post-transplantation hypertension is associated with 
increased renal sodium retention (Graf et al., 1993). Other mechanisms involve in the 
pathophysiology of post-transplantation hypertension remain unclear. Studies on renal 
plasma flow and GFR (Rettig et al., 1990), renal and plasma renin-angiotensin systems 
(Rettig et al., 1994), and renal α-adrenoceptor density (Michel et al., 1992) do not show 
differences in the respective traits that could be associated with this form of 
hypertension. Also, there is no sympathetic reinnervation of the grafted kidney during 
the development of renal post-transplantation hypertension, thus the effects of the 
recipients sympathetic nervous system are of limited importance for the development 
of renal post-transplantation hypertension (Grisk et al., 2000). 
 Clinical studies have produced similar data, and it was first demonstrated that in 
patients who received a renal transplant from a donor with a family history of 
hypertension, mean arterial pressure was significantly higher than in patients whose 
donor family had a normotensive history (Guidi et al., 1996). Whereas, patients who 
received a transplant from a hypertensive donor had higher blood pressures compared 
with patients who received kidneys from normotensive donors (Strandgaard and 
Hansen, 1986). Finally, transplantation of a kidney from a normotensive donor 
produced a sustained normalisation of arterial pressure in hypertensive patients who 
had demonstrated long-standing essential hypertension (Curtis et al., 1983). These 
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clinical data emphasize the importance of the kidney in the development and 
maintenance of hypertension in humans and experimental animals. 
 Transplant studies have established the role of the kidney in arterial blood 
pressure regulation, but the intrinsic renal mechanisms that regulate arterial pressure 
are not revealed by these experiments. The kidney could influence blood pressure 
regulation by altering renal afferent nerve activity (DiBona and Koop, 1997), releasing 
vasoactive factors into the circulation (Bergstrom et al., 1998), or by altering 
extracellular fluid volume through a number of different mechanisms (Cowley and 
Roman, 1996). Chronic alterations in renal adrenergic activity achieved either by renal 
denervation or long-term infusions of norepinephrine directly into the renal artery, alter 
pressure natriuresis and produce sustained changes in arterial pressure (Reinhart et 
al., 1995; Lohmeier et al. 2000). 
 
1.1.3.a   Medullary circulation in the long-term regulation of arterial pressure 
The renal medulla receives only a small fraction (10%) of total renal blood flow, 
and the flow per unit of tissue weight is only approximately 30 – 60% of that in the 
cortex (Pallone et al. 1990, 2000), yet its microcirculation appears to play a critical role 
in the long-term maintenance of arterial pressure via its influence on sodium and water 
reabsorption (Cowley, 1997; Bergstrom and Evans, 2000). This appears to be 
mediated mainly through the influence of medullary blood flow (MBF) on tubular 
reabsorption of salt and water (Cowley, 1997).  
Based on pharmacological studies, it has been suggested that changes in 
blood flow in the renal medulla is an important mechanism in the regulation of sodium 
and water excretion, and dilation of the renal medullary circulation can have a 
natriuretic and/or diuretic effect (Lameire et al., 1980; Fadem et al., 1982). A direct 
increase in renal perfusion pressure (RPP) leads to an increased sodium and water 
excretion in the isolated perfused kidney (Aperia et al., 1971; Tobian et al., 1978), and 
kidneys studied in vivo (Roman and Cowley, 1985; Roman, 1988; Roman et al., 1988; 
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Majid et al., 1993, 1997, 1998) in the absence of measurable changes in whole kidney 
RBF or GFR. In addition, the hydrostatic pressure in the postglomerular capillaries in 
the renal cortex, the peritubular capillaries, is also constant as RPP is increased 
(Roman and Cowley, 1985; Roman et al., 1988). However, blood flow in the vasa recta 
capillaries of the renal medulla was demonstrated to increase directly with RPP despite 
the autoregulation of GFR and RBF in normal mice, rats, and dogs (Roman et al., 
1988; Strick et al., 1989; Farrugia et al., 1993; Mattson et al., 1993; Huang et al., 1994; 
Bergstrom et al., 1998; Gross et al., 1998a, 1998b). The increase in flow in the vasa 
recta capillary bed in the renal medulla is coincident with an increase in vasa recta 
hydrostatic pressure (Roman et al., 1988), increased renal interstitial hydrostatic fluid 
pressure (Roman et al., 1988; Garcia-Estan and Roman, 1989; Patel et al., 1994), 
decreased reabsorption of sodium and water from the proximal segments of deep 
nephrons (Haas et al., 1986; Roman, 1988), and increased excretion of sodium and 
water (Roman and Cowley, 1985; Roman et al., 1988). 
Experiments by Mattson et al., (1994) and Makino et al., (2002) have shown 
that a selective and sustained decrease in medullary perfusion can lead to retention of 
sodium and development of hypertension. Continuous renal medullary interstitial 
infusion of L-NAME in the normotensive Sprague-Dawley rats significantly decreased 
renal medullary blood flow by 30%, and was accompanied by a significant retention of 
sodium, an increase in body weight, and the development of hypertension. Renal 
medullary blood flow returned to normal levels, a negative sodium balance was 
observed, and blood pressure returned to levels not different from control when the 
interstitial L-NAME infusion was discontinued (Mattson et al., 1994) without any change 
in renal cortical blood flow (Makino et al., 2002).  
Changes in resistance in renal cortical vessels can also have a profound impact 
on blood flow to the medulla as any change in inflow resistance will be reflected in 
blood flow in the downstream segments of the renal medulla, and the likely sites 
involved are the preglomerular resistance vessels, i.e. the afferent arterioles (Mattson, 
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2003). In summary, the medullary circulation is important in the long-term regulation of 
fluid and electrolyte balance, and blood pressure. Direct long-term alterations in renal 
medullary blood flow can lead to changes in sodium and water excretion which may be 
translated into sustained alterations in sodium balance and a new level of arterial blood 
pressure. 
 
1.1.3.b  Influences of Ang II on renal medullary circulation. 
Renal vessels, in general, and especially in SHR are more sensitive to 
catecholamines, Ang II, and also calcium channel blockers (CCBs) than the systemic 
resistance vessels (Loutzenhiser and Epstein, 1990). The CCBs affect mainly the 
afferent arteriole (Fleming et al., 1987; Cacellas and Moore, 1990) and so do the α1-
adrenoceptor blocker. Both, Ang II and catecholamines, have been shown to constrict 
preglomerular vessels in isolated arteries (Edwards, 1983), in isolated kidneys 
(Steinhausen et al., 1990), and in vivo (Chatziantoniou and Arendshorst, 1992).  
Similar to Ang II, nervous stimulation has been reported to affect both afferent and 
efferent resistances (Hermansson et al., 1981). The effect of nervous stimulation also 
be facilitated by increased Ang II levels as Ang II is an important mediator of the 
contraction of resistance vessels during nervous stimulation in rats (Pelayo et al., 
1984).  
Ang II is a major mediator of the regulation of glomerular filtration through its 
combined control of the vascular tone in both arterioles. Ang II has been shown to have 
a vasoconstrictor effect on the renal medullary circulation (Faubert et al., 1987; 
Pallone, 1994), no influence on the medullary circulation (Mattson et al., 1991; Mattson 
and Roman, 1991), or even an increase in medullary blood flow with high doses of Ang 
II (Nobes et al., 1991). Prostaglandin (Cupples et al., 1988; Mattson and Roman, 1991; 
Pallone, 1994), nitric oxide (Zou et al., 1997; Szentizvanyi et al., 1999, 2002), and 
kinins (Nobes et al., 1991) attenuate the vasoconstrictor action of Ang II in the 
medullary circulation. Szentizvanyi et al. (2002) reported an inherited defect in the 
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ability of Dahl salt-sensitive rat to produce nitric oxide within the outer medulla of the 
kidney along with a failure of medullary nitric oxide concentrations to increase in 
response to Ang II in this strain. As a result, small elevations of circulating Ang II that 
have no effect in normal rats lead to hypertension in Dahl salt-senstive rats. 
The net effect of Ang II on blood flow in the renal medulla in vivo appears to be 
due to increased resistance in the efferent arterioles of the juxtamedullary nephrons 
(Carmines et al., 1986) and/or due to direct effects of Ang II to constrict the DVR 
(Pallone, 1994). Yet, the net effect of changes in circulating Ang II in the physiological 
range on medullary blood flow in conscious rats is minimal (Gross et al., 1998), 
possibly due to antagonistic actions of different vasodilatory factors. 
In addition, the mechanism of the decrease in medullary blood flow appears to 
be due to a combination of a reduction in renal cortical blood flow (Leonard et al., 
2000) as well as direct actions of norepinephrine to vasoconstrict the DVR (Yang et al., 
1995). Pharmacological studies have demonstrated that the sympathetic 
neurotransmitter norepinephrine decreases renal medullary perfusion via stimulation of 
α1-adrenoceptors (Zou and Cowley, 2000). 
 
1.1.4  Renal innervation 
The sympathetic nervous system (SNS) plays an important role in arterial 
pressure regulation. This system regulates the total and regional peripheral resistance 
and capacitance of the vascular system mainly through changes following release of 
catecholamines from both the sympathetic nerve terminals and the adrenal medulla 
gland (Guimaraes and Moura, 2001), and binding of the catecholamines to the 
adrenergic receptors. 
The mechanisms by which the SNS regulates arterial pressure acutely and 
chronically are quite different (Guyton, 1980), hence, acute blood pressure responses 
to either sympathetic stimulation or inhibition may not be generalised into the 
contribution of the SNS to the chronic maintenance of arterial pressure. The activity of 
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the SNS is important for rapid adjustments of cardiovascular and renal function in 
response to changing environment conditions. Its involvement in long term arterial 
pressure regulation remains unclear due to a lack of reliable methods or technical 
limitations to chronically quantify sympathetic activity, and adaptation of the nervous 
system to repeatedly applied stimuli, for example, central and peripheral resetting of 
baroreflexes, and to determine the sustained influence of the sympathetic nervous 
system on sodium excretion (Lohmeier et al., 2001). Numerous acute studies 
demonstrating that Ang II actually increases sympathetic activity (Reid, 1992; Fink, 
1997), but yet it is fascinating to discover that chronic baroreflex-mediated suppression 
of renal sympathetic nervous activity (RSNA) is the compensatory response to Ang II 
hypertension leading to attenuation of the antinatriuretic and hypertensive effect of Ang 
II (Carrol et al., 1984; Cox and Bishop, 1991; Lohmeier et al., 2001). However, there is 
little chronic data to support the contention that the sympathetic nervous system 
contributes to Ang II hypertension (Reid, 1992; Fink, 1997). 
In addition to short lasting effects on organ function, the sympathetic nervous 
system may also induce chronic effects on target organs, manifested as altered DNA, 
protein synthesis and changes in organ morphology. SHR are characterised by 
increased sympathetic innervation of their internal organs compared to normotensive 
animals. Selective surgical renal denervation in young SHR delays, but does not 
prevent, the development of arterial hypertension, and complete neonatal 
sympathectomy induces a long term reduction of arterial pressure in SHR. Hence, of 
how reduction in sympathetic tone affects long term blood pressure in SHR is 
dependent on the stage during ontogeny at which it is applied, and on the extent to 
which sympathetic influences are removed. The specific organ affected is also a 
contributing factor. Since the kidney appears to be the major determinant of long term 
blood pressure in SHR, studying the specific role of early sympathetic activation within 
this organ for the development of hypertension in this model is a prospect to consider. 
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The kidney has very dense sympathetic innervations, and neuroeffector 
junctions have been described along most of the vascular and tubular elements of the 
tissue (Coote et al., 1972; Johns et al., 1976). Renal sympathetic nerve activity (RSNA) 
plays a significant role in the regulation of renal haemodynamics and excretory function 
(Malpas et al., 1996; DiBona and Koop, 1997; Malpas and Evans, 1998; DiBona, 2000; 
Leonard et al., 2001). Renal nerves modulate RBF variability in several physiological 
conditions, such as exerting an antihypertensive effect when renal perfusion pressure 
is reduced, and RSNA is increased during hypoxia or hemorrhage (Janssen et al., 
1997; Malpas et al., 1998, 1999; Nafz et al., 2000; Zou and Cowley, 2000; Barret et al., 
2001). 
At a functional level, high levels of direct electrical stimulation of the renal 
sympathetic nerves resulted in frequency related decreases in RBF (Sattar and Johns, 
1994a, 1994b; Armenia et al., 2004), GFR and renin release (Coote et al., 1972 and 
Johns et al., 1976). One of the groundbreaking reports was that of LaGrange and his 
co-workers (1973) who observed that electrical stimulation of the renal nerves at low 
levels, which had no measurable impact on renal haemodynamics, still caused a large 
decrease in sodium and water excretion. These observations laid the foundation for the 
concept that the renal nerves could directly act on the tubular epithelial cells of the 
proximal tubule (Bello-Reuss et al., 1976) and thick limb of the loop of Henle (DiBona 
and Sawin, 1982) to increase the rate of fluid transport from lumen to interstitium. 
Currently, it is considered that graded activation of the renal sympathetic nerves 
progressively recruits a number of functions, initially stimulating renin release from the 
granular juxtaglomerular cells; thereafter sodium absorption is raised; while at the 
highest rates reductions in blood flow and glomerular filtration occur (Osborn and 
Johns, 1989; DiBona and Kopp, 1997). Together, these reports support the view that 
the neural control of sodium reabsorption by the kidney is exerted at levels that have 
minimal effects on renal haemodynamics.  
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RSNA has been shown to be important in the control of total RBF (Malpas et 
al., 1996; Malpas and Evans, 1998), yet its role in the control of regional kidney blood 
flow remains unclear. RSNA may have a profound effect on the long-term control of 
arterial pressure mediated via effects on the medullary microcirculation. In addition to 
the multiple effects of sympathetic nerve stimulation on kidney function (DiBona and 
Koop, 1997), renal nerve stimulation differentially decreases blood flow in the renal 
cortex and medulla (Rudenstam et al., 1995; Leonard et al., 2000, 2001). The renal 
nerves might differently regulate cortical (or total renal) blood flow (CBF) and MBF 
through different frequency response characteristics of the vasculature in these two 
regions. MBF appears to be less sensitive to sympathetic nerve activity than CBF, 
regardless of whether the nerves are activated by electrical stimulation (Leonard et al., 
2000) or reflexively (Leonard et al., 2001), but sensitivity within these vascular 
territories appears to be relatively homogenous (Guild et al., 2002). 
The medullary insensitivity is particularly evident at relatively low stimulus 
intensities, as might occur under physiological conditions (Rudenstam et al., 1995; 
Leonard et al., 2000, 2001) despite juxtamedullary efferent arterioles (mEA) having 
more layers of smooth muscle cells (Kriz, 1981; Helou and Marchetti, 1997; Pallone et 
al., 1998), and denser innervation (Gorgas, 1978) than superficial or outer cortical 
efferent arterioles. This may be due to the influence of α2-receptor stimulation by 
norepinephrine in the medulla to increase the release of NO, which opposes the 
vasoconstrictor effects of norepinephrine (Zou and Cowley, 2000). Also, differences in 
the density and organization of vascular network and vascular structure (Kriz, 1981; 
Pallone et al., 1990), density and distribution of innervations (Barajas and Powers, 
1990), or the kinetics of smooth muscle contraction between cortical and medullary 
vascular sites may result in a difference in the ability to respond to the different 
frequencies in RSNA. 
The renal sympathetic nerves represent one primary mechanism by which 
kidney fluid reabsorption can be modulated, and via the consequent increase or 
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decrease in extracellular fluid volume can have a major impact on blood pressure. The 
renal nerves appear to be the critical link between the SNS and long-term regulation of 
arterial pressure, because they impact renal excretory function (Guyton, 1980). 
Sympathetic nervous system responds chronically, as well as acutely, to regulate body 
fluid volumes and arterial pressure. It has been demonstrated that suppression of 
RSNA and attendant increments in renal excretory function are long-term responses to 
excess body fluid volumes and hypertension (Lohmeier and Hildebrandt, 1998; 
Lohmeier et al., 1998, 1999, 2000). During high salt intake or hypertension induced by 
chronic intravenous infusion of either norepinephrine or Ang II, there is a relative 
increase in sodium excretion from innervated as compared to denervated kidneys 
(Lohmeier and Hildebrandt, 1998; Lohmeier et al., 1998, 1999, 2000). This indicates 
that RSNA is suppressed in these states of chronic volume excess and/or 
hypertension. 
It has also been determined that the chronic suppression of RSNA in Ang II 
hypertension is abolished by denervation of sinoaortic and cardiopulmonary 
baroreceptors, suggesting that baroreflexes play a critical role in the long-term 
response (Lohmeier et al., 2000). Subjecting rats to coartation of the aorta to produce 
an abrupt and constant increase in arterial pressure, and from recording of aortic 
baroreceptor activity during anaesthesia, Krieger (1986) concluded that complete 
baroreceptor resetting occurs within 48 hr of hypertension. Another study by Cowley 
and DeClue (1976), by inducing a rapid and sustained increase in arterial pressure by 
chronic infusion of Ang II in dogs with and without sinoaortic denervation, showed that 
acute increases in arterial pressure in response to Ang II were more pronounced after 
deafferentation of arterial baroreceptors than before when the arterial barorefllex was 
intact. However, the increase in blood pressure was equal in both groups, and finally 
the arterial pressures on day 7 of Ang II infusion were comparable. Thus, the 
baroreceptors appeared to have no sustained influence on the severity of the 
